title: [81mKr scintigraphic evaluation of hemodynamics in gynecologic malignancies under condition of angiotensin II-induced hypertension].
abstract: Transcatheter arterial infusion chemotherapy is one of the most useful therapeutic procedures for gynecologic malignancies. Recently, several reports have been published about Angiotensin II-induced hypertension chemotherapy and the efficacy of the method, but there have been no reports to evaluate an application for gynecologic malignancies. We evaluate the usefulness of the method for gynecologic malignancies demonstrating the changes of hemodynamics of the tumor using 81mKr scintigraphy. Thirteen patients with pathologically confirmed gynecologic malignancies were evaluated by angiography and continuous infusion of 81mKr via the catheter with and without Angiotensin II. At first, continuous infusion of 81mKr was performed under the superselective catheterization of the uterine artery. The radioactivities in the ROI were counted. Then, withdrew the catheter from the uterine artery to the internal iliac artery, and again continuously infused 81mKr and counted the radioactivities in the same ROI. Finally, keeping the catheter in the internal iliac artery, Angiotensin II and 81mKr were infused simultaneously. And counted the radioactivities. The radioactivities were highest when the catheter tip was placed in uterine arteries and lowest when the catheter tip was placed in internal iliac arteries. But radioactivities in the ROIs were definitely increased when Angiotensin II was used, even if the catheter tip was keeping in the internal iliac arteries. The optimal catheter position of transcatheter arterial chemotherapy for gynecologic malignancies is at proximal uterine artery. Since Angiotensin II-induced hypertension may increase blood flow of tumors, it seems to have indication for post-operative cases, highly advanced cases and cases with difficulties to perform superselective catheterization.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Radiology, Juntendo Urayasu Hospital.
authors.forename: Y
authors.initials: Y
authors.lastname: Sumi
authors.forename: Y
authors.initials: Y
authors.lastname: Ozaki
authors.forename: K
authors.initials: K
authors.lastname: Amemiya
authors.forename: S
authors.initials: S
authors.lastname: Kyogoku
authors.forename: A
authors.initials: A
authors.lastname: Shirakata
authors.forename: F
authors.initials: F
authors.lastname: Tamamoto
authors.forename: H
authors.initials: H
authors.lastname: Katayama
authors.forename: H
authors.initials: H
authors.lastname: Utsuno
authors.forename: T
authors.initials: T
authors.lastname: Kubota
mesh_terms: D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D002406:Catheterization, Peripheral; D005260:Female; D006439:Hemodynamics; D006801:Humans; D007261:Infusions, Intra-Arterial; D007727:Krypton Radioisotopes / Q000008:administration & dosage; D008875:Middle Aged; D011877:Radionuclide Imaging; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy; D014594:Uterine Neoplasms / Q000000981:diagnostic imaging* / Q000503:physiopathology / Q000628:therapy; D014599:Uterus / Q000098:blood supply*
chemical_list: D007727:Krypton Radioisotopes; D000804:Angiotensin II